Research Summary

My main research interests are in understanding how diet, exercise, other lifestyle factors, and genetics contribute to cancer progression and death. Our program aims to identify modifiable lifestyle risk factors for cancer progression, use this information to better understand cancer biology, and inform public health guidelines. I have worked in this area, with a specific focus on prostate cancer, for ~20 years. Our work is highly collaborative - our clinical and translational studies work to identify risk-reduction strategies for men with or at high risk for prostate cancer, evaluate novel molecular markers of prostate cancer aggressiveness that may improve screening, diagnosis, or prognosis of clinically relevant disease, and improve cancer survivorship for the millions of men living with prostate cancer worldwide.

I lead the Diet and Lifestyle Study within the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE); am PI of a randomized clinical trial examining an exercise intervention among men pursuing active surveillance for prostate cancer; co-PI on a large Dept. of Defense Translational Impact Award focused on improving risk stratification and decision support for men considering active surveillance for low risk prostate cancer; serve on the steering committee for a global clinical trial of exercise among men with metastatic prostate cancer; and am co-investigator on a trial examining a 2 year remotely monitored blended diet and exercise intervention for men undergoing surgery for prostate cancer. I also collaborate with team members on lifestyle interventions and observational research in bladder and colorectal cancer survivors.

Research Funding

  • April 14, 2014 - February 28, 2020 - Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer Prognosis, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA181802
  • September 1, 2006 - August 31, 2011 - Prostate Microenvironmental &Prostate Cancer Progression, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA106947
  • April 14, 2014 - February 28, 2020 - Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer Prognosis, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA181802
  • September 1, 2006 - August 31, 2011 - Prostate Microenvironmental &Prostate Cancer Progression, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA106947

Education

Harvard College, Cambridge, MA , B.A., 1994, Applied Math in Biology
Harvard School of Public Health, Boston, MA, ScD, 11/98, Epidemiology (Cancer)
Harvard School of Public Health, Boston, MA, 11/98-11/00, Postdoctoral Fellow-Epidemiology

Honors & Awards

  • 1994-96
    Fulbright Scholar, Uppsala University, Sweden, Dept. of Medical Epidemiology
  • 1996 & 1997
    Pforzheimer Public Service Fellowship, Harvard University
  • 1998
    Society for Epidemiologic Research Abraham Lilienfeld Student Prize
  • 1998
    Association for the Cure of Cancer of the Prostate ("CaPCURE") - Young Investigator Award
  • 2000
    AACR-AFLAC Young Investigator Scholars in Cancer Research Award
  • 2001
    REAC Intramural award, UCSF
  • 2002
    AACR-California Department of Health Services Early Career Development Award in Gender-Related Cancer Research (prostate)
  • 2003
    Prostate Cancer Foundation ("CaPCURE") - Competitive Award (6/03 & 12/03)
  • UCSF Equal Opportunity Faculty Development Award
  • 2009
    Awarded Steven & Christine Burd-Safeway Distinguished Professorship, Urology, UCSF

Selected Publications

  1. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 Oct 12.  View on PubMed
  2. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021 Nov; 206(5):1147-1156.  View on PubMed
  3. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Reply by Authors. J Urol. 2021 Nov; 206(5):1156.  View on PubMed
  4. Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urol Oncol. 2021 Oct; 39(10):730.e9-730.e15.  View on PubMed
  5. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Kageyama R, Wells DK, Chan JM, Friedlander T, Aggarwal R, Paris PL, Feng F, Carroll PR, Witte JS. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precis Oncol. 2021; 5.  View on PubMed
  6. Langlais CS, Chan JM, Kenfield SA, Cowan JE, Graff RE, Broering JM, Carroll P, Van Blarigan EL. Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history. Cancer Causes Control. 2021 Jun; 32(6):635-644.  View on PubMed
  7. Gaylis FD, Cooperberg MR, Chen RC, Malin J, Loeb S, Witte JS, Carroll PR, Cohen ES, Dato PE, Lin DW, Zheng Y, Seibert TM, Setzler C, Wilt W, Gomez SL, Chan JML, Catalona WJ. Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience. Letter. J Urol. 2021 07; 206(1):171-172.  View on PubMed
  8. Langlais CS, Graff RE, Van Blarigan EL, Palmer NR, Washington SL, Chan JM, Kenfield SA. Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality. Curr Oncol Rep. 2021 03 10; 23(3):37.  View on PubMed
  9. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 Mar 03; 11(1):5040.  View on PubMed
  10. Chan JM, Van Blarigan EL, Langlais CS, Zhao S, Ramsdill JW, Daniel K, Macaire G, Wang E, Paich K, Kessler ER, Beer TM, Lyons KS, Broering JM, Carroll PR, Kenfield SA, Winters-Stone KM. Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. J Med Internet Res. 2020 12 31; 22(12):e19238.  View on PubMed
  11. Wang EY, Graff RE, Chan JM, Langlais CS, Broering JM, Ramsdill JW, Kessler ER, Winters-Stone KM, Van Blarigan EL, Kenfield SA. Web-Based Lifestyle Interventions for Prostate Cancer Survivors: Qualitative Study. JMIR Cancer. 2020 Nov 10; 6(2):e19362.  View on PubMed
  12. Langlais CS, Chan JM. Opportunities and challenges for research on low-carbohydrate diets in prostate cancer. Nat Rev Urol. 2020 Aug; 17(8):437-438.  View on PubMed
  13. Zuniga KB, Borno H, Chan JM, Van Blarigan EL, Friedlander TW, Wang S, Zhang L, Kenfield SA. The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer. J Racial Ethn Health Disparities. 2020 10; 7(5):996-1002.  View on PubMed
  14. Van Blarigan EL, Kenfield SA, Chan JM, Van Loon K, Paciorek A, Zhang L, Chan H, Savoie MB, Bocobo AG, Liu VN, Wong LX, Laffan A, Atreya CE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP. Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial. Cancer Epidemiol Biomarkers Prev. 2020 04; 29(4):752-760.  View on PubMed
  15. Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR. Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. Cancer Med. 2020 01; 9(1):125-132.  View on PubMed
  16. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. J Urol. 2019 10; 202(4):702-709.  View on PubMed
  17. Cedars BE, Washington SL, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2019 10; 202(4):696-701.  View on PubMed
  18. Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, Carroll PR, Chan JM. Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer. J Urol. 2019 10; 202(4):689-695.  View on PubMed
  19. Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM. Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1917-1925.  View on PubMed
  20. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020 03; 23(1):136-143.  View on PubMed

Go to UCSF Profiles, powered by CTSI